Venetoclax (Venclexta) da kuma rituximab (Rituxan) ana amfani da su a hade tare da sake dawowa / cutar sankarar sankarar bargo ta lymphocytic ( Cll ), wanda ke haifar da babban adadin ƙarancin cutar da ba a iya ganewa ba ( UMRD ), wanda ke da alaƙa da rayuwa mai ƙarancin ci gaba mai ɗorewa ( PFS ).
Venetoclax da marasa lafiyar da aka kula dasu sun kusan kusan sau 5 matsayin uMRD kamar yadda suka haɗu da phenytoin da rituximab, kuma yawan marasa lafiyar da suka kiyaye wannan matsayin a cikin watanni 24 ya fi girma a cikin ƙungiyar venetoclax / rituximab ɗin 20 ko fiye. Idan aka kwatanta da matsayin MRD- tabbatacce, uMRD yana da alaƙa da raguwar 62% cikin haɗarin ci gaban cuta ko mutuwa.
The MRD status has been proven to predict PFS in CLL patients treated with chemoimmunotherapy , but the predictive value of MRD for new drugs remains uncertain. Data from the random MURANO trial provides an opportunity to examine the predictive value of MRD and CLL without chemotherapy.
MURANO wani lokaci ne na III wanda bazuwar gwaji wanda ke kimanta ingancin rituximab haɗe tare da venetoclax da bendamustine a cikin marasa lafiya 389 tare da koma baya / ƙin yarda CLL. Mai haƙuri ya karɓi shekaru 2 na venetoclax da watanni 6 na farko na rituximab, ko watanni 6 na bendamustine da rituximab na watanni 6.
Binciken farko ya nuna cewa idan aka kwatanta da rituximab da bendamustine, haɗarin ci gaban cuta ko mutuwa ya kasance 84% a cikin shekaru 3 na jiyya tare da venetoclax da rituximab.
